Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2016-11-10 Earnings Release
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2016. It reports the issuance of a press release announcing financial results for the third quarter ended September 30, 2016. The document explicitly states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The text of the 8-K itself does not contain detailed financial statements or substantive financial data but rather announces the release of the earnings information. The document length is 3360 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing the earnings release but not containing the full financial results should be classified as an Earnings Release (ER).
2016-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the removal of a partial clinical hold by the FDA on a clinical study and mentions a press release dated November 9, 2016. It also references a conference call scheduled for November 10, 2016, to discuss the third quarter results, but the document itself does not contain financial statements or detailed financial data. The document is short (4119 characters) and primarily serves as an announcement of an event and a press release. Therefore, it is not an earnings release, interim report, or annual report. It is also not a management change, voting result, or other specific category. Given the nature of the filing and the lack of substantive financial data, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2016-11-09 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2016. The key content is under Item 5.02, which announces the appointment of Tal Zaks to the Board of Directors as an independent Non-Executive Director and his membership on the Remuneration Committee. This is a clear announcement of a change in the company's board of directors. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is specifically about management/board changes, fitting the Board/Management Information category.
2016-11-08 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 27, 2016. The key content is under Item 5.02, which announces the departure and appointment of directors and officers. It specifically mentions the appointment of Giles Kerr to the Board of Directors and the planned retirement of Ian Laing from the Board. There is no financial data or detailed report content; rather, it is an announcement of changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is 3313 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2016-10-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the announcement of a material definitive agreement (a clinical trial collaboration agreement) and a lease agreement, as well as a press release attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is primarily an announcement of significant corporate events and agreements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-10-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a press release about the initiation of a Phase I clinical study and a strategic alliance, which is furnished as an exhibit. There are no financial statements or detailed financial data presented. The document is relatively short (4250 characters) and primarily serves to announce an event and provide the press release as an exhibit. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2016-10-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.